Bortezomib: A Review of its Use in Patients with Multiple Myeloma

ISSN： 0012-6667

Source： Drugs, Vol.69, Iss.7, 2009-05, pp. : 859-888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of the proteasome inhibitor bortezomib in multiple myeloma

By Richardson Paul G

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1321-1331

Informa Healthcare

Access to resources Recommend Favorite

Plerixafor: A Review of its Use in Stem-Cell Mobilization in Patients with Lymphoma or Multiple Myeloma

By Keating Gillian M.

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1623-1647

Adis International

Access to resources Recommend Favorite

The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite